Patients 3-10 days post ACS without HF/LVSD but ? natriuretic peptides

1
N1101
Patients 3-10 days post ACS without HF/LVSD but ?
natriuretic peptides
Standard Medical Therapy
NT-proBNP Aldosterone
Blinded Therapy
Placebo
Aliskiren
Valsartan
Valsartan /Aliskiren
4 wks
Dose up-titration over 2 weeks
NT-proBNP
Dose up-titration of 2nd agent over 2
weeks (placebo in 3 arms and active in combo arm)
4 wks
NT-proBNP Aldosterone
End of Study
Biomarker Endpoint ? NT-proBNP and ?
Aldosterone Clinical Endpoint CV death,
recurrent MI, HF hospitalization